Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Czechsinthemail who wrote (705)	2/4/1998 8:22:00 AM
From: BD	Read Replies (1) \| Respond to of 887

Intresting story. The management changes do foretell either ineptness in the FDA submittal or that someone knew about a problem and didn't disclose it. I lean in the direction of ineptness. If there was a problem with the technology I would think that the board would have known about it. An FDA submittle is altogether different and you either have the experience to do it right to avoid problems or you don't. If this was the cause, the good news is that it likely can be corrected.

To: Czechsinthemail who wrote (705)	2/4/1998 8:42:00 AM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 887

DEPO is scheduled to talk with the FDA at the end of this month. The slight delay is not a bad thing as it will give them more time to assemble the data from their Phase IV DepoCyt trial. The trial has enrolled 40 patients as planned. But, the data are not all in yet. Of the enrolled patients 2 have died for reasons unrelated to DepoCyt and 2 were eliminated due to improper intrathecal catheter placements. DEPO claims that adherence to the prescription for also taking steroids to reduce headaches is better in this trial. The administrative reshuffling is troublesome. The fact that the company felt it necessary to reduce the workforce to reduce the burn rate when they have around $30MM in cash suggests that they are planning for a long term recovery before looking to refinance again. They are, in the local parlance, "hunkering down". This predicts that there will not be a dilution of stock value anytime soon and that they don't expect a large infusion of capital from any potential partners anytime soon also. John de C